AFM
TPST icon

Anson Funds Management’s Tempest Therapeutics TPST Stock Holding History

Anson Funds Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,713
Closed -$715K – 302
2020
Q4 		$715K Sell
1,713
-104
-6% -$36K 0.14% 117
2020
Q3 		$577K Buy
+1,817
New +$616K 0.31% 72
2017
Q1 		– Sell
-142
Closed -$637K – 79
2016
Q4 		$637K Buy
+142
New +$1.77M 0.2% 42

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Anson Funds Management's TPST Position: Q1 2021 in Review

Anson Funds Management sold out of Tempest Therapeutics (TPST) in Q1 2021, closing a stake of 1,713 shares — an estimated $715K sold.

Anson Funds Management first reported a position in TPST in Q4 2016 and held it in 3 quarters. The position peaked at $715K in Q4 2020. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2021.

  • Anson Funds Management reported no remaining Tempest Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Anson Funds Management sold 1,713 Tempest Therapeutics shares in Q1 2021, an estimated $715K.
  • Anson Funds Management first reported a position in Tempest Therapeutics in Q4 2016 and held it in 3 quarters.
  • Anson Funds Management's Tempest Therapeutics position peaked at $715K in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.